Nearly one in four people worldwide may not have it vaccinated against the new coronavirus before 2022 at least, because the richest countries, which account for less than 15% of the world’s population, have blocked 51% of the doses of the most promising vaccines, researchers said on Tuesday.
Low- and middle-income countries, home to the remaining 85% of the world’s population, should be content with the remaining, according to a study by researchers at Johns Hopkins University School of Public Health in Bloomberg.
To respond effectively to the pandemic, richer countries are required to “distribute” vaccines, to ensure “fair distribution of vaccines around the world,” the researchers said.
“The uncertainty about global access to vaccines is due not only to the fact that clinical trials are still ongoing, but also to the fact that governments and companies producing vaccines are no longer transparent about the agreements they are concluding,” the researchers said. by Johns Hopkins.
The largest orders
By November 15, the highest-income states had already pre-ordered 7.5 billion doses of vaccines produced by 13 pharmaceutical industries, according to the study.
Among those countries are Japan, Australia and Canada – all three of which have pre-ordered over 1 billion doses, although they account for less than 1% of active cases of the new coronavirus, the researchers said.
SOS by organizations
Even if the largest vaccine industries reach their peak production capacity, nearly 25% of the world’s population may not have been immunized before at least a year, if not longer, warn, researchers warn.
The People’s Vaccine Alliance ruled last week that pharmaceutical companies would have to share their technology and intellectual property through the World Health Organization so that more vaccine doses could be produced.
Researchers at Johns Hopkins point out that the COVAX mechanism, the World Health Organization’s SARS-CoV-2 vaccination program, could play a key role in guaranteeing fairer access to approved vaccines. , a number more than four times its target, which is to distribute at least 2 million doses of vaccine by the end of 2021.
The program, announced in April, aims to raise funds from richer countries and non-profit organizations to accelerate the development and production of vaccines against the new coronavirus and ensure their fair distribution around the world.
So far, it has raised half the funding it needs, while the United States and Russia – key countries in developing and producing vaccines – have not joined, according to a study by Johns Hopkins researchers.